166 related articles for article (PubMed ID: 25141892)
1. UGT1A1*28 polymorphisms: a potential pharmacological biomarker of irinotecan-based chemotherapies in colorectal cancer.
Liu X; Xu W
Pharmacogenomics; 2014 Jun; 15(9):1171-4. PubMed ID: 25141892
[No Abstract] [Full Text] [Related]
2. UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.
Sunakawa Y; Ichikawa W; Fujita K; Nagashima F; Ishida H; Yamashita K; Mizuno K; Miwa K; Kawara K; Akiyama Y; Araki K; Yamamoto W; Miya T; Narabayashi M; Ando Y; Hirose T; Saji S; Sasaki Y
Cancer Chemother Pharmacol; 2011 Aug; 68(2):279-84. PubMed ID: 20957480
[TBL] [Abstract][Full Text] [Related]
3. Prospective phase II study of FOLFIRI for mCRC in Japan, including the analysis of UGT1A1 28/6 polymorphisms.
Okuyama Y; Hazama S; Nozawa H; Kobayashi M; Takahashi K; Fujikawa K; Kato T; Nagata N; Kimura H; Oba K; Sakamoto J; Mishima H
Jpn J Clin Oncol; 2011 Apr; 41(4):477-82. PubMed ID: 21303789
[TBL] [Abstract][Full Text] [Related]
4. Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
Chen S; Hua L; Feng C; Mo Q; Wei M; Shen Y; Lin Z; Li G; Xu J; Guo C; Huang H
BMC Gastroenterol; 2020 Apr; 20(1):96. PubMed ID: 32264830
[TBL] [Abstract][Full Text] [Related]
5. [The role of assessing UGT1A1 gene polymorphism in the prediction of irinotecan-induced toxicity in the course of chemotherapy for colorectal cancer].
Kit OI; Vladimirova LY; Vodolazhskiy DI; Abramova NA; Dvadnenko KV
Vopr Onkol; 2015; 61(2):266-9. PubMed ID: 26087609
[TBL] [Abstract][Full Text] [Related]
6. Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting.
Lu CY; Huang CW; Hu HM; Tsai HL; Huang CM; Yu FJ; Huang MY; Chang SF; Huang ML; Wang JY
Transl Res; 2014 Aug; 164(2):169-76. PubMed ID: 24462762
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
Lentz F; Tran A; Rey E; Pons G; Tréluyer JM
Am J Pharmacogenomics; 2005; 5(1):21-33. PubMed ID: 15727486
[TBL] [Abstract][Full Text] [Related]
8. Prospective analysis of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab plus FOLFIRI as the first-line setting: study protocol for a randomized controlled trial.
Yeh YS; Tsai HL; Huang CW; Wang JH; Lin YW; Tang HC; Sung YC; Wu CC; Lu CY; Wang JY
Trials; 2016 Jan; 17():46. PubMed ID: 26811156
[TBL] [Abstract][Full Text] [Related]
9. UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy.
Martinez-Balibrea E; Abad A; Martínez-Cardús A; Ginés A; Valladares M; Navarro M; Aranda E; Marcuello E; Benavides M; Massutí B; Carrato A; Layos L; Manzano JL; Moreno V
Br J Cancer; 2010 Aug; 103(4):581-9. PubMed ID: 20628391
[TBL] [Abstract][Full Text] [Related]
10. UGT1A polymorphisms associated with worse outcome in colorectal cancer patients treated with irinotecan-based chemotherapy.
Yu Q; Zhang T; Xie C; Qiu H; Liu B; Huang L; Peng P; Feng J; Chen J; Zang A; Yuan X
Cancer Chemother Pharmacol; 2018 Jul; 82(1):87-98. PubMed ID: 29728798
[TBL] [Abstract][Full Text] [Related]
11. DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan.
Falvella FS; Cheli S; Martinetti A; Mazzali C; Iacovelli R; Maggi C; Gariboldi M; Pierotti MA; Di Bartolomeo M; Sottotetti E; Mennitto R; Bossi I; de Braud F; Clementi E; Pietrantonio F
Br J Clin Pharmacol; 2015 Sep; 80(3):581-8. PubMed ID: 25782327
[TBL] [Abstract][Full Text] [Related]
12. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer.
Toffoli G; Cecchin E; Corona G; Russo A; Buonadonna A; D'Andrea M; Pasetto LM; Pessa S; Errante D; De Pangher V; Giusto M; Medici M; Gaion F; Sandri P; Galligioni E; Bonura S; Boccalon M; Biason P; Frustaci S
J Clin Oncol; 2006 Jul; 24(19):3061-8. PubMed ID: 16809730
[TBL] [Abstract][Full Text] [Related]
13. Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
Liu D; Li J; Gao J; Li Y; Yang R; Shen L
BMC Cancer; 2017 Jun; 17(1):437. PubMed ID: 28637434
[TBL] [Abstract][Full Text] [Related]
14. Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer.
Fujii H; Yamada Y; Watanabe D; Matsuhashi N; Takahashi T; Yoshida K; Suzuki A
Cancer Chemother Pharmacol; 2019 Jan; 83(1):123-129. PubMed ID: 30377777
[TBL] [Abstract][Full Text] [Related]
15. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients.
Rouits E; Boisdron-Celle M; Dumont A; Guérin O; Morel A; Gamelin E
Clin Cancer Res; 2004 Aug; 10(15):5151-9. PubMed ID: 15297419
[TBL] [Abstract][Full Text] [Related]
16. A UGT1A1*28 and *6 genotype-directed phase I dose-escalation trial of irinotecan with fixed-dose capecitabine in Korean patients with metastatic colorectal cancer.
Kim KP; Kim HS; Sym SJ; Bae KS; Hong YS; Chang HM; Lee JL; Kang YK; Lee JS; Shin JG; Kim TW
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1609-17. PubMed ID: 23595344
[TBL] [Abstract][Full Text] [Related]
17. Correlative analysis of plasma SN-38 levels and DPD activity with outcomes of FOLFIRI regimen for metastatic colorectal cancer with UGT1A1 *28 and *6 wild type and its implication for individualized chemotherapy.
Cai X; Tian C; Wang L; Zhuang R; Zhang X; Guo Y; Lu H; Wang H; Li X; Gao J; Li Q; Wang C
Cancer Biol Ther; 2017 Mar; 18(3):186-193. PubMed ID: 28278081
[TBL] [Abstract][Full Text] [Related]
18. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer.
Glimelius B; Garmo H; Berglund A; Fredriksson LA; Berglund M; Kohnke H; Byström P; Sørbye H; Wadelius M
Pharmacogenomics J; 2011 Feb; 11(1):61-71. PubMed ID: 20177420
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance.
Butzke B; Oduncu FS; Severin F; Pfeufer A; Heinemann V; Giessen-Jung C; Stollenwerk B; Rogowski WH
Acta Oncol; 2016; 55(3):318-28. PubMed ID: 26098842
[TBL] [Abstract][Full Text] [Related]
20. Association between UGT1A1*28 polymorphisms and clinical outcomes of irinotecan-based chemotherapies in colorectal cancer: a meta-analysis in Caucasians.
Liu X; Cheng D; Kuang Q; Liu G; Xu W
PLoS One; 2013; 8(3):e58489. PubMed ID: 23516488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
